Estrella Immunopharma, Inc.
ESLAHealthcare|Biotechnology|US
$0.38
-0.03 (-8.49%)
DCF Value
$0.02
Cash / Share
$0.00
Financials
Financial Snapshot
Market Cap
$16.3M
Enterprise Value
$16.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$10.0M
Cash & Investments
$146.7K
Net Cash
$146.7K
Free Cash Flow (TTM)
-$9.4M
Operating CF (TTM)
-$9.4M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$146.7K
Quarterly Burn
$2.3M
Monthly Burn
$782.0K
Est. Runway
~0.1 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | — | $4.1M | $40.8K | $4.2M | $916.9K | $1.4M | $146.7K | |
| Operating Cash Flow | -$670.8K | -$1.4M | -$1.0M | -$16.1M | -$3.1M | -$1.8M | -$9.4M | |
| Free Cash Flow | -$670.8K | -$1.4M | -$1.0M | -$16.1M | -$3.1M | -$1.8M | -$9.4M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | -$4.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $670.8K | $5.5M | -$35.6M | $12.8M | -$135.0K | $2.3M | $8.2M |
R&D Spending
R&D (TTM)
$7.0M
R&D Intensity
—
R&D Growth vs Prior
-31.9%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $457.2K | $1.4M | $10.5M | $4.1M | $6.4M | $10.2M | $7.0M | |
| SG&A | $276.5K | $296.2K | $663.2K | $3.2M | $2.4M | $2.8M | $2.8M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $457.2K | $1.4M | $10.5M | $4.1M | $6.4M | $10.2M | $7.0M | |
| SG&A | $276.5K | $296.2K | $663.2K | $3.2M | $2.4M | $2.8M | $2.8M | |
| Operating Income | -$733.7K | -$1.7M | -$11.1M | -$7.3M | -$8.8M | -$13.1M | -$9.8M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$733.7K | -$1.7M | -$11.1M | -$7.3M | -$8.8M | -$13.1M | -$10.0M | |
| Net Income | -$733.7K | -$1.7M | -$11.1M | -$7.3M | -$8.8M | -$13.1M | -$10.0M | |
| EPS (Diluted) | -0.02 | -0.05 | -0.32 | -0.21 | -0.24 | -0.35 | -0.25 | |
| EBITDA | -$733.7K | -$1.7M | -$11.1M | -$7.3M | -$8.8M | -$13.1M | -$9.8M | |
| Shares Out. (M) | 35.20 | 35.20 | 35.20 | 35.20 | 36.68 | 36.82 | 43.00 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | — | $4.1M | $40.8K | $4.2M | $916.9K | $1.4M | $146.7K | |
| Short-Term Investments | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | — | $4.9M | $52.4K | $4.5M | $1.6M | $1.7M | $1.8M | |
| Total Assets | — | $4.9M | $10.0M | $4.5M | $3.1M | $3.2M | $1.8M | |
| Total Current Liabilities | — | $946.7K | $1.1M | $180.7K | $3.0M | $13.5M | $9.3M | |
| Long-Term Debt | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | — | $6.0M | $2.9M | $180.7K | $3.0M | $13.5M | $9.3M | |
| Stockholders' Equity | — | -$1.0M | $7.1M | $4.3M | $143.7K | -$10.4M | -$7.4M | |
| Retained Earnings | — | -$1.1M | -$2.3M | -$19.5M | -$23.9M | -$37.0M | -$41.6M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$670.8K | -$1.4M | -$1.0M | -$16.1M | -$3.1M | -$1.8M | -$9.4M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | -$4.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$670.8K | -$1.4M | -$1.0M | -$16.1M | -$3.1M | -$1.8M | -$9.4M | |
| Investing Cash Flow | $0.00 | $0.00 | $36.2M | $5.0M | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $670.8K | $5.5M | -$35.6M | $12.8M | -$135.0K | $2.3M | $8.2M | |
| Issuance of Stock | $0.00 | $15.0K | $0.00 | $0.00 | $79.5K | $2.4M | $9.0M | |
| Repurchase of Stock | $0.00 | $0.00 | -$36.1M | -$354.4K | -$214.5K | -$29.5K | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $498.6K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $62.9K | $130.0K | $0.00 | $1.2M | $0.00 | $0.00 | $446.1K | |
| Net Change in Cash | $0.00 | $4.1M | -$438.1K | $1.7M | $876.1K | $467.4K | -$1.2M |
Dilution Tracker
Shares Outstanding
43M
5-Year Share Growth
+4.6%
Stock Issuance (TTM)
$9.0M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 35.20 | 35.20 | 35.20 | 35.20 | 36.68 | 36.82 | 43.00 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | 4.2% | 0.4% | 16.8% | |
| Stock Issuance | $0.00 | $15.0K | $0.00 | $0.00 | $79.5K | $2.4M | $9.0M | |
| Stock Repurchase | $0.00 | $0.00 | -$36.1M | -$354.4K | -$214.5K | -$29.5K | $0.00 | |
| Stock Based Comp. | $62.9K | $130.0K | $0.00 | $1.2M | $0.00 | $0.00 | $446.1K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 0.0% | 162.1% | -157.2% | -171.1% | -6155.7% | 126.0% | 121.7% | |
| ROA % | 0.0% | -34.2% | -111.3% | -164.2% | -281.7% | -411.2% | -548.7% | |
| ROIC % | 0.0% | -3.4% | -118.1% | -51.5% | -6154.5% | 126.0% | 131.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -129.7% | -559.5% | 34.2% | -21.0% | -47.7% | |
| Net Income | 0.0% | -129.7% | -559.5% | 34.2% | -21.0% | -47.6% | |
| EPS (Diluted) | 0.0% | -130.3% | -568.1% | 34.4% | -14.3% | -45.8% | |
| Operating Cash Flow | 0.0% | -115.0% | 27.6% | -1439.3% | 80.6% | 42.6% | |
| Free Cash Flow | 0.0% | -115.0% | 27.6% | -1439.3% | 80.6% | 42.6% | |
| R&D Expense | 0.0% | 203.8% | 652.4% | -60.7% | 56.0% | 59.9% | |
| SG&A Expense | 0.0% | 7.2% | 123.9% | 382.7% | -23.9% | 15.5% | |
| Total Assets | 0.0% | 0.0% | 102.9% | -55.4% | -29.5% | 1.2% | |
| Book Value / Share | 0.0% | 0.0% | 780.0% | -39.6% | -96.8% | -7284.7% | |
| Debt | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 4.2% | 0.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-2.17
10Y Low / Med / High9.06 / 51.23 / 306.25
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.02
Cash / Share
$0.00
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -468.75 | -206.89 | -32.16 | -5.24 | -5.00 | -4.46 | -1.52 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | -335.48 | 51.23 | 9.06 | 306.25 | -5.54 | -2.17 | |
| EV/EBITDA | 0.00 | -204.56 | -32.63 | -4.73 | -4.87 | -4.29 | -1.65 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-53.37
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.2M | -$11.8M | -$11.4M |
| EPS | $-0.25 | $-0.32 | $-0.31 |
| # Analysts (EPS) | 1 | 1 | 1 |